| DC8856 |
EPI-001
Featured
|
EPI-001 is an androgen receptor N-terminal domain antagonist with IC50 of ∼6 μM and a selective PPAR-gamma modulator |
|
| DC8693 |
Epiandrosterone
Featured
|
Epiandrosterone is a steroid hormone with weak androgenic activity. Epiandrosterone is naturally produced by the enzyme 5α-reductase from the adrenal hormone DHEA. |
|
| DC23071 |
Epigoitrin
Featured
|
Epigoitrin and fructopyrano-(1→4)-glucopyranose(FG) from the traditional Chinese medicine Isatidis radix, exhibit in vitro cooperation, they have in vitro anti-virus activity. |
|
| DC9467 |
Epinastine
Featured
|
Epinastine(WAL801) is an antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis.
|
|
| DCAPI1014 |
Eplerenone
Featured
|
Eplerenone, also known as Inspra and CGP-30083, is a selective aldosterone receptor antagonist used to treat hypertension and congestive heart failure. Eplerenone provides marked protection against vascular injury in the kidney and heart.
|
|
| DC4198 |
Epothilone B
Featured
|
Epothilone B is a Taxol-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. |
|
| DC8030 |
Epoxomicin
Featured
|
Epoxomicin is a selective and irreversible inhibitor of 20S proteasome with an IC50 value of 4 nM. |
|
| DC12311 |
Eprobemide (LIS 630)
Featured
|
Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A. |
|
| DC9260 |
Eptapirone
Featured
|
Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family. |
|
| DC5182 |
EPZ004777
Featured
|
EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM. |
|
| DC7121 |
EPZ005687
Featured
|
EPZ-005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases. |
|
| DC7927 |
EPZ011989
Featured
|
EPZ011989 is a potent, orally-available EZH2 Inhibitor. |
|
| DC8012 |
EPZ015666
Featured
|
EPZ015666 is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs. |
|
| DC9267 |
EPZ015866
Featured
|
EPZ015866(GSK591) is a potent, selective PRMT5 inhibitor. |
|
| DC26000 |
EPZ019997
Featured
|
EPZ019997 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). |
|
| DC9822 |
EPZ020411 HCl
Featured
|
EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has ＞10 fold selectivity for PRMT6 over PRMT1 and PRMT8. |
|
| DC10887 |
EPZ031686
Featured
|
EPZ031686 is a noncompetitive inhibitor for SMYD3 and MEKK2 with a Ki=1.2 and 1.1 nM respectively. |
|
| DC4242 |
Pinometostat(EPZ5676)
Featured
|
EPZ-5676 is a small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. |
|
| DC7122 |
Tazemetostat(EPZ-6438)
Featured
|
EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity with Ki value of 2.5±0.5 nM. |
|
| DC20997 |
ER000444793
Featured
|
ER-000444793 is a potent, cyclophilin D-independent inhibitor of mitochondrial permeability transition pore (mPTP) with with IC50 of 2.8 uM. |
|
| DC7410 |
Erastin
Featured
|
Erastin is a compound that interacts with VDAC, blocked and reversed mitochondrial depolarization after microtubule destabilizers in intact cells and antagonized tubulin-induced VDAC blockage in planar bilayers. |
|
| DC11387 |
Erdafitinib
Featured
|
Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively. |
|
| DC23055 |
Erianin
Featured
|
Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis. |
|
| DCAPI1539 |
Eribulin Mesylate
Featured
|
Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma. |
|
| DC26018 |
ERK5-IN-2
Featured
|
ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. |
|
| DC22486 |
Erlotinib mesylate
Featured
|
Erlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). Erlotinib HCl was approved. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. When erlotinib binds to EGFR, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated. |
|
| DC2101 |
Erlotinib free base
Featured
|
Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
|
| DC3139 |
Erlotinib hydrochloride
Featured
|
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
|
| DCAPI1477 |
Ertapenem
Featured
|
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. |
|
| DCAPI1476 |
Ertapenem Sodium
Featured
|
Ertapenem Sodium |
|
